Combination of Immune Checkpoint Therapy with Antibody-Drug Conjugate (ADC)

Antibody-Drug Conjugate (ADC)

The distinctive composition of ADCs, comprising an antibody (or antibody fragment), a chemical linker, and a cytotoxic payload, confers upon this category of therapeutic biological agent not only precision in target recognition but also formidable potency. The integration of immune checkpoint therapy with ADCs in combination strategies has the potential to bolster antineoplastic efficacy. The implicated mechanisms are diverse, encompassing the induction of immunogenic cell demise, maturation of dendritic cells, augmentation of T lymphocyte infiltration, as well as the amplification of immunological memory and the expression of immune-regulatory molecules, including programmed death ligand (PD-L)1 and MHC.

Advantages of Combination of Immune Checkpoint Therapy With ADC

• The integration of immuno-oncology combination strategies, such as the conjunction of ADCs with ICIs, represents a compelling avenue in therapeutic development. ADCs' potent cytotoxic delivery holds the potential to enhance antigen presentation by augmenting the liberation of tumor antigens from apoptotic cancer cells. Moreover, this antigen presentation process can be further amplified through direct actions of the unbound payload and the stimulation of maturation and activation in antigen-presenting dendritic cells.
• The ADC-induced immunogenic cell demise (ICD) may substantially contribute to the antitumor immune response. Further enhancements in the precision of target antigen recognition and drug delivery efficacy of ADCs have the potential to refine and amplify this synergistic mechanism.

Case Study

Creative Biolabs is professional in this field, offering comprehensive support for diverse drug development initiatives pertaining to immune checkpoints. Presently, an array of tailored solutions for the integration of immune checkpoint therapy with ADC is accessible through Creative Biolabs, encompassing, but not limited to: Immune Checkpoint Antibody Development, Immune Checkpoint Assays, Immune Checkpoint Targeted Peptide Development, etc. Please contact us for comprehensive information.

References

1. Li, Bin, et al. "Immune checkpoint inhibitors combined with targeted therapy: the recent advances and future potentials." Cancers 15.10 (2023): 2858.
2. Under Open Access license CC BY 4.0, without modification.

All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic, or any in vivo human use.